Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Don M Benson

Showing results (71-80 of 110) with videos related to

Pageof 11
Sort By:
Cancers|November 26, 2022
Longitudinal Survival Outcomes in Allogeneic Stem Cell Transplantation: An Institutional ExperienceJustin Jiang, Audrey M Sigmund, Qiuhong Zhao, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2020
Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple MyelomaSarah A Holstein, Vera J Suman, Kouros Owzar, et al.
Blood|October 28, 2011
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effectDon M Benson, Courtney E Bakan, Shuhong Zhang, et al.
British Journal of Haematology|April 8, 2015
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphomaBeth A Christian, Ming Poi, Jeffrey A Jones, et al.
International Immunology|June 6, 2018
Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemiaNathaniel J Buteyn, Kavin Fatehchand, Ramasamy Santhanam, et al.
Leukemia & Lymphoma|December 1, 2012
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myelomaNeil C Dunavin, Lai Wei, Patrick Elder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphomaKhuda D Khan, Christos Emmanouilides, Don M Benson, et al.
Immunity|May 23, 2006
Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cellsJianhua Yu, Min Wei, Brian Becknell, et al.
Molecular Cancer|June 26, 2010
The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activityMatthew A Bill, James R Fuchs, Chenglong Li, et al.
Blood|November 18, 2006
Hlx homeobox transcription factor negatively regulates interferon-gamma production in monokine-activated natural killer cellsBrian Becknell, Tiffany L Hughes, Aharon G Freud, et al.
Pageof 11

Showing results (71-80 of 110) with videos related to

Sort By:
Pageof 11
Cancers|November 26, 2022
Longitudinal Survival Outcomes in Allogeneic Stem Cell Transplantation: An Institutional ExperienceJustin Jiang, Audrey M Sigmund, Qiuhong Zhao, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2020
Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple MyelomaSarah A Holstein, Vera J Suman, Kouros Owzar, et al.
Blood|October 28, 2011
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effectDon M Benson, Courtney E Bakan, Shuhong Zhang, et al.
British Journal of Haematology|April 8, 2015
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphomaBeth A Christian, Ming Poi, Jeffrey A Jones, et al.
International Immunology|June 6, 2018
Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemiaNathaniel J Buteyn, Kavin Fatehchand, Ramasamy Santhanam, et al.
Leukemia & Lymphoma|December 1, 2012
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myelomaNeil C Dunavin, Lai Wei, Patrick Elder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphomaKhuda D Khan, Christos Emmanouilides, Don M Benson, et al.
Immunity|May 23, 2006
Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cellsJianhua Yu, Min Wei, Brian Becknell, et al.
Molecular Cancer|June 26, 2010
The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activityMatthew A Bill, James R Fuchs, Chenglong Li, et al.
Blood|November 18, 2006
Hlx homeobox transcription factor negatively regulates interferon-gamma production in monokine-activated natural killer cellsBrian Becknell, Tiffany L Hughes, Aharon G Freud, et al.
Pageof 11